Latest Conference Articles

DUO-E Trial Data Support Durvalumab Combo as Potential Frontline Option in Advanced Endometrial Cancer

Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.

Lenvatinib Plus Pembrolizumab Displays Survival Benefit in Subgroups of Patients With Endometrial Cancer

Lenvatinib plus pembrolizumab did not best chemotherapy in pMMR endometrial cancer, but did offer a survival benefit in some subgroups of patients.

Experts Share Top Highlights from the 2024 SGO Annual Meeting on Women’s Cancer

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology

Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.

AI Models May Serve As Additional Genetic Counseling Resource in Gynecologic Oncology

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Disparities in Care Outcomes Persist Between Black and White Patients With Endometrioid Endometrial Carcinoma

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Dr Hayek on Laparoscopic vs Open Surgery in Advanced Ovarian Cancer

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Nab-Sirolimus Elicits Responses in Gynecologic/Peritoneal PEComa

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell Carcinoma

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Dr Corvigno on Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Mirvetuximab Soravtansine Associated With Improved HRQOL in FRα+ Ovarian Cancer

Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.

SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Olaparib Plus Cediranib Falls Short in All-Comers With Platinum-Resistant or Refractory Ovarian Cancer

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

Dostarlimab Plus Chemo Demonstrates Survival Advantage in Advanced Endometrial Cancer

Dostarlimab plus carboplatin/paclitaxel improved overall survival vs placebo plus chemotherapy in primary advanced or recurrent endometrial cancer.

Quad Shot Radiation Plus Immunotherapy Improves Local Control in Advanced Head and Neck Cancer

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

Pembrolizumab Plus Chemo Generates Favorable OS Trend in Endometrial Cancer

The addition of pembrolizumab to chemotherapy led to a favorable overall survival benefit vs chemotherapy plus placebo in endometrial cancer.

Social Determinants of Health Linked With Varying Cervical Cancer Rates in the US

Social determinants of health were associated with geographical variations in the rates of cervical cancer in the United States.

Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal Cancer

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Mutter Discusses Partial Breast Irradiation in Low-Risk Breast Cancer

Robert W. Mutter, MD, discusses the nuances of partial breast irradiation in early-stage breast cancer.

Post-Hoc Analysis Shows Dose-Escalated Radiation is Safe and Efficacious in Intrahepatic Cholangiocarcinoma

A post-hoc analysis showed dose escalation of radiation therapy was safe and elicited similar efficacy in intrahepatic cholangiocarcinoma.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Dr Knight on the Investigation of Patients With Brain-Metastatic Prostate Adenocarcinoma

James Knight, MD, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma.

Dr Efstathiou on the Role of Tri-Modality Therapy in MIBC

Jason Efstathiou, MD, DPhil, discusses the role of tri-modality therapy in patients with muscle-invasive bladder cancer.

Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung Cancer

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.